Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
Author:
Affiliation:
1. College of Medicine, Chang Gung University, Taipei, Taiwan
2. Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan
3. Liver Research Unit, Chang Gung Memorial Hospital, Taiwan
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Hepatology
Reference5 articles.
1. Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?;Liaw;Hepatology,2023
2. Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis;Jeng;Hepatology,2023
3. Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis;Jeng;Hepatology,2023
4. Finite nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: An emerging paradigm shift;Liaw;Hepatol Int,2019
5. Systematic review: Cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B;Chang;Aliment Pharmacol Ther,2015
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3